Arctic Bioscience AS
OSL: ABS.OL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christer L. Valderhaug
- Employees
- 22
- Headquarters
- Ørsta, Norway
- IPO year
- 2021
- Market cap
- NOK 92.7M
- Website
- https://www.arctic-bioscience.com
Loading ABS…
Loading profile data…Frequently asked questions about ABS
What does Arctic Bioscience AS (ABS.OL) do?
Arctic Bioscience AS, a biotechnology company, develops and commercializes pharmaceutical and nutraceutical products. Its development stage product candidate is HRO350, a novel oral treatment for mild-to-moderate psoriasis. The company sells its nutraceuticals as bulk ingredients to other companies under the ROMEGA brand worldwide. Arctic Biosci...
Where does ABS.OL trade?
Arctic Bioscience AS (ABS.OL) trades on the Oslo Stock Exchange.
What sector is ABS.OL in?
Arctic Bioscience AS (ABS.OL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arctic Bioscience AS?
Christer L. Valderhaug is the chief executive officer of Arctic Bioscience AS (ABS.OL).
Where is Arctic Bioscience AS headquartered?
Arctic Bioscience AS is headquartered in Norway.
Does ABS.OL pay a dividend?
Arctic Bioscience AS (ABS.OL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ABS.OL go public?
Arctic Bioscience AS (ABS.OL) completed its initial public offering in 2021.